Following completion of the scoping process and the NICE Medicines Optimisation Team briefing, it has been confirmed that this appraisal will be routed to the cost comparison process.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-January 2025 when we will write to you about how you can get involved.